An autologous tumor-infiltrating lymphocyte therapy for the treatment of advanced melanoma
Iovance Biotherapeutics, Inc. completes their BLA submission for Lifileucel – an autologous tumor infiltrating lymphocyte (TIL) therapy (manufactured using PBMC feeder cells) for the treatment of advanced (unresectable or metastatic) melanoma who have progressed on or after prior anti-PD-1/L1 therapy and targeted therapy, where applicable. There are no FDA approved therapies in this treatment setting. Furthermore, this is the first TIL cell therapy BLA submission ever submitted to the FDA. Here’s to a bright future for these patients, Iovance, and all involved!
